CHU de Quebec-Universite Laval
chudequebec.caLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
137
Active
39
Phase 3
8
Total enrollment
79,537
Pipeline matrix
Showing 19 of 19 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Target trough IgG level of 8-10 g/L | — | — | — | — | — | 1 | |
| Target trough IgG level 4-6 g/L | — | — | — | — | — | 1 | |
| No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L | — | — | — | — | — | 1 | |
| Enzalutamide | — | — | — | — | — | 1 | |
| Bicalutamide | — | — | — | — | — | 1 | |
| Control Arm | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| 177Lu-Octreotate | — | — | — | — | — | 1 | |
| Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute | — | — | — | — | — | 1 | |
| Self assembled skin substitute | — | — | — | — | — | 1 | |
| MAG-EPA | — | — | — | — | — | 1 | |
| 177Lu-PSMA-I&T - escalating renal absorbed dose | — | — | — | — | — | 1 | |
| 177Lu-PSMA-I&T - recommended phase 2 regime | — | — | — | — | — | 1 | |
| SASS | — | — | — | — | — | 1 | |
| Cholesterol metabolism disruption | — | — | — | — | — | 1 | |
| Androgen Deprivation Therapy | — | — | — | — | — | 1 | |
| Drug (Dutasteride) intervention first | — | — | — | — | — | 1 | |
| Dexmedetomidine | — | — | — | — | — | 1 | |
| lidocaine | — | — | — | — | — | 1 |
Next readouts
- 2016-12-31
- 2019-12-24
- 2023-12-12
- 2024-09-01
- 2025-01-31
- 2025-04-12
- 2025-11-01
- 2026-09-01
- 2027-04
- 2028-01
Top conditions
- Prostate Cancer14
- Preeclampsia4
- Insomnia4
- Breast Cancer4
- Bone Health4
- Traumatic Brain Injury4
- Quality of Life4
- Preterm Birth3
Frequently asked questions about CHU de Quebec-Universite Laval
- How many clinical trials does CHU de Quebec-Universite Laval have on ClinicalTrials.gov?
- CHU de Quebec-Universite Laval is listed as the lead sponsor on 137 clinical trials in ClinicalTrials.gov, 39 of which are currently active (recruiting, enrolling, or ongoing).
- How many of CHU de Quebec-Universite Laval's trials are in Phase 3?
- 8 of CHU de Quebec-Universite Laval's trials are in Phase 3, spread across 19 active drug programs.
- What therapeutic areas does CHU de Quebec-Universite Laval focus on?
- CHU de Quebec-Universite Laval's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Preeclampsia, Insomnia, Breast Cancer, Bone Health.
- When are CHU de Quebec-Universite Laval's next clinical trial readouts?
- CHU de Quebec-Universite Laval has 10 upcoming primary-completion readouts tracked here; the soonest is “Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression”, expected around 2016-12-31.